Program
molnupiravir
Also written as “Molnupiravir”, “EIDD-2801” and “MK-4482”.
Its studies are mostly in COVID-19 · Renal Insufficiency · Coronavirus Infections, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 91 open or running | phase 3since Sep 30, 2020 | Sep 30, 2020 | Jan 26, 2031phase 3 · NCT06667700 |
| Ridgeback Biotherapeutics, LP | 30 open or running | phase 2since May 26, 2020 | Apr 29, 2020 | none ahead |
| Geropharm | 10 open or running | no phasesince Dec 7, 2022 | Dec 7, 2022 | none ahead |
| Valenta Pharm JSC | 10 open or running | no phasesince Jun 6, 2022 | Jun 6, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 29, 2020First study: phase 1 study in Coronavirus InfectionsNew to Ridgeback Biotherapeutics, LPRidgeback Biotherapeutics, LP · NCT04392219 · 130 enrolled · United Kingdom
- May 26, 20202 phase 2 studiesRidgeback Biotherapeutics, LP · NCT04405739, NCT04405570
- Sep 30, 2020Merck's first studies: 2 phase 3 studies in COVID-19New to MerckMerck · NCT04575597, NCT04575584
- Jun 24, 2021Phase 3 study in COVID-19Merck · NCT04939428 · 2,441 enrolled · United States, Argentina, Brazil and more
- May 18, 20222 phase 1 studiesMerck · NCT05386758, NCT05386589
- Jun 6, 2022Valenta Pharm JSC's first study: no phase study in Virus DiseasesNew to Valenta Pharm JSCValenta Pharm JSC · NCT05412173 · 37 enrolled · Russian Federation
- Sep 26, 2022Phase 2 study in Respiratory Syncytial VirusMerck · NCT05559905 · 116 enrolled · United Kingdom
- Dec 7, 2022Geropharm's first study: no phase study in COVID-19New to GeropharmGeropharm · NCT05648799 · 246 enrolled · Russian Federation
- Sep 24, 2024Phase 1 study in HealthyMerck · NCT06615869 · 64 enrolled · United States
- Oct 30, 2024Phase 3 study in COVID-19Merck · NCT06667700 · 3,082 planned · United States, Argentina, Brazil and more
- Feb 4, 2025Phase 1 study in COVID-19Merck · NCT06816030 · 16 enrolled · China
Ahead
- Jan 26, 2031Primary completion: phase 3 study in COVID-19Merck · NCT06667700
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RNA disrupting agent”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06816030COVID-19 · China | 1 | Completed | Merck | Aug 5, 2023 | 16 |
| NCT06667700COVID-19 · United States, Argentina, Brazil and more | 3 | Recruiting | Merck | Jan 26, 2031 | 3,082 |
| NCT06615869Healthy · United States | 1 | Completed | Merck | Feb 27, 2023 | 64 |
| NCT05648799COVID-19 · Russian Federation | – | Completed | Geropharm | May 11, 2022 | 246 |
| NCT05559905Respiratory Syncytial Virus · United Kingdom | 2 | Completed | Merck | Apr 18, 2023 | 116 |
| NCT05412173Virus Diseases · Russian Federation | – | Completed | Valenta Pharm JSC | May 17, 2022 | 37 |
| NCT05386758Renal Insufficiency · United States | 1 | Completed | Merck | Feb 4, 2023 | 16 |
| NCT05386589Hepatic Impairment · United States | 1 | Completed | Merck | Dec 18, 2022 | 14 |
| NCT04939428COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Merck | Nov 16, 2022 | 2,441 |
| NCT04575597COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Merck | May 5, 2022 | 1,735 |
| NCT04575584COVID-19 · United States, Brazil, Canada and more | 3 | Terminated | Merck | Aug 11, 2021 | 304 |
| NCT04405739SARS-CoV 2 · United States | 2 | Completed | Ridgeback Biotherapeutics, LP | Feb 21, 2022 | 71 |
| NCT04405570COVID-19 · United States | 2 | Completed | Ridgeback Biotherapeutics, LP | Feb 21, 2021 | 204 |
| NCT04392219Coronavirus Infections · United Kingdom | 1 | Completed | Ridgeback Biotherapeutics, LP | Aug 11, 2020 | 130 |
How it is read
Names in the registry
- “Molnupiravir”, 9 entries
- “EIDD-2801”, 2 entries
- “MK-4482”, 1 entry
- “GP30341 capsules 200 mg”, 1 entry
- “Molnupiravir 200 mg”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 8 studies
- Renal Insufficiency, 1 study
- Coronavirus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.